Pfizer/BioNTech COVID-19 vaccine: MHRA statement
Wednesday, 18 November 2020 17:58
MHRA CEO Dr June Raine said: The results reported by Pfizer today
are very encouraging and add to their announcement from last week.
We look forward to receiving the full results of the trials as soon
as possible, after which we will rigorously assess the evidence of
safety and effectiveness of the...Request free trial
MHRA CEO Dr June Raine
said:
The results reported by Pfizer today are very
encouraging and add to their announcement from last
week.
We look forward to receiving the full results of the
trials as soon as possible, after which we will
rigorously assess the evidence of safety and
effectiveness of the vaccine.
Approval process for a potential COVID-19 vaccine
- There are two routes to obtain a COVID-19 vaccine
approval: through a full marketing authorisation or
through a temporary authorisation route known as
regulation 174.
- As regulation 174 is a public health-related
measure, manufacturers cannot apply for this
authorisation, it is the Government that requests the
MHRA approval for specific products as part of a public
health response.
- The MHRA will apply the key criteria of safety,
quality and efficacy before authorising the use of a
vaccine under either route.
- This means that, for both routes, once the data is
submitted our scientists and clinicians will carefully
and scientifically review the safety, quality and
effectiveness data – how it protects people from
COVID-19 and the level of protection it provides. The
data must include results from the lab and clinical
trials in humans; manufacturing and quality controls;
product sampling; and testing of the final product.
- The safety of the public will always come first. A
COVID-19 vaccine will only be approved for use via
either route once it has met robust standards on
safety, effectiveness and quality through clinical
trials.
- For both routes, we will rigorously assess the data
in the shortest time possible, without compromising the
thoroughness of our review.
- Once we have thoroughly reviewed the data via
either route, we will seek advice from the Government’s
independent advisory body, the Commission on
Human Medicines. The Commission will critically
assess the data too before advising the UK government
on the safety, quality and effectiveness of any
potential vaccine.
- While a vaccine is approved by us, the Joint
Committee on Vaccination and Immunisation will
advise the government about the use of the vaccine.
- The MHRA is globally recognised for requiring the
highest standards of safety, quality and effectiveness
for any vaccine.
|